The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use

The use of the myocardial cytoprotector trimetazidine in a patient with angina as an example of off-label use

The clinical case of the successful use of the myocardial cytoprotector trimetazidine as a universal anti-ischemic agent in a patient with hemodynamic angina due to myocardial bridging is described. The pathogenetic rationale for this prescription is presented.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika 2019-12, Vol.18 (6), p.116-120
Hauptverfasser: Tsygankova, O. V., Latyntseva, L. D., Batluk, T. I., Platonov, D. Yu, Akhmedzhanov, N. M.
Format: Artikel
Sprache:eng ; rus
Schlagworte:
hemodynamic angina
off-label use
trimetazidine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The clinical case of the successful use of the myocardial cytoprotector trimetazidine as a universal anti-ischemic agent in a patient with hemodynamic angina due to myocardial bridging is described. The pathogenetic rationale for this prescription is presented.
ISSN:1728-8800
2619-0125
DOI:10.15829/1728-8800-2019-6-116-120